Jump to content

2-Oxazolidinone: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m Cleaned up using AutoEd
Filled in 1 bare reference(s) with reFill 2
Line 83: Line 83:
* [[Radezolid]] (RX-1741) has completed some phase-II clinical trials.<ref>{{cite web|url=http://www.rib-x.com/pipeline/rx_1741 |title=Rx 1741 |publisher=Rib-X Pharmaceuticals |year=2009 |access-date=2009-05-17 |url-status=dead |archive-url=https://web.archive.org/web/20090226201337/http://www.rib-x.com/pipeline/rx_1741 |archive-date=2009-02-26 }}</ref>
* [[Radezolid]] (RX-1741) has completed some phase-II clinical trials.<ref>{{cite web|url=http://www.rib-x.com/pipeline/rx_1741 |title=Rx 1741 |publisher=Rib-X Pharmaceuticals |year=2009 |access-date=2009-05-17 |url-status=dead |archive-url=https://web.archive.org/web/20090226201337/http://www.rib-x.com/pipeline/rx_1741 |archive-date=2009-02-26 }}</ref>
* [[Cycloserine]] is a second line drug against [[tuberculosis]]. Note that cycloserine, while technically an oxazolidone, has a different mechanism of action and substantially different properties from the aforementioned compounds.
* [[Cycloserine]] is a second line drug against [[tuberculosis]]. Note that cycloserine, while technically an oxazolidone, has a different mechanism of action and substantially different properties from the aforementioned compounds.
* [[Contezolid]] (S)-5-((isoxazol-3-ylamino)methyl)-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-2-one ([[MRX-I]]) has reported phase 1 data<ref>{{cite journal|doi=10.1021/jm401931e | volume=57 | issue=11 | title=New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile | year=2014 | journal=Journal of Medicinal Chemistry | pages=4487–4497 | last1 = Gordeev | first1 = Mikhail F. | last2 = Yuan | first2 = Zhengyu Y.}}</ref> and completed phase II trials in 2015, and is starting a phase 3 trial in 2016.<ref>[http://www.prnewswire.com/news-releases/micurx-initiates-phase-3-clinical-trial-for-mrx-i-a-new-potent-oral-antibiotic-against-gram-positive-bacteria-including-mrsa-300346800.html MicuRx Initiates Phase 3 Clinical Trial for MRX-I... 2016]</ref>
* [[Contezolid]] (S)-5-((isoxazol-3-ylamino)methyl)-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-2-one ([[MRX-I]]) has reported phase 1 data<ref>{{cite journal|doi=10.1021/jm401931e | volume=57 | issue=11 | title=New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile | year=2014 | journal=Journal of Medicinal Chemistry | pages=4487–4497 | last1 = Gordeev | first1 = Mikhail F. | last2 = Yuan | first2 = Zhengyu Y.}}</ref> and completed phase II trials in 2015, and is starting a phase 3 trial in 2016.<ref>{{Cite web|url=https://www.prnewswire.com/news-releases/micurx-initiates-phase-3-clinical-trial-for-mrx-i-a-new-potent-oral-antibiotic-against-gram-positive-bacteria-including-mrsa-300346800.html|title=MicuRx Initiates Phase 3 Clinical Trial for MRX-I, A New Potent Oral Antibiotic Against Gram-positive Bacteria, Including MRSA|first=MicuRx Pharmaceuticals|last=Inc|website=www.prnewswire.com}}</ref>
An oxazolidinone derivative used for other purposes is [[rivaroxaban]], which is approved by the FDA for venous thromboembolism prophylaxis.
An oxazolidinone derivative used for other purposes is [[rivaroxaban]], which is approved by the FDA for venous thromboembolism prophylaxis.


Revision as of 15:53, 9 March 2023

2-Oxazolidone
Names
Preferred IUPAC name
1,3-Oxazolidin-2-one
Other names
2-Oxazolidone
2-Oxazolidinone
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.007.129 Edit this at Wikidata
KEGG
UNII
  • InChI=1S/C3H5NO2/c5-3-4-1-2-6-3/h1-2H2,(H,4,5) checkY
    Key: IZXIZTKNFFYFOF-UHFFFAOYSA-N checkY
  • InChI=1/C3H5NO2/c5-3-4-1-2-6-3/h1-2H2,(H,4,5)
    Key: IZXIZTKNFFYFOF-UHFFFAOYAE
  • O=C1OCCN1
Properties
C3H5NO2
Molar mass 87.077 g/mol
Appearance Solid
Melting point 86 to 89 °C (187 to 192 °F; 359 to 362 K)
Boiling point 220 °C (428 °F; 493 K) at 48 torr
Related compounds
Related compounds
 Oxazolidine
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

2-Oxazolidone is a heterocyclic organic compound containing both nitrogen and oxygen in a 5-membered ring.

Oxazolidinones

Evans auxiliaries

Oxazolidinones are a class of compounds containing 2-oxazolidone in the structure. In chemistry, they are useful as Evans auxiliaries, which are used for chiral synthesis. Usually, the acid chloride substrate reacts with the oxazolidinone to form an imide. Substituents at the 4 and 5 position of the oxazolidinone direct any aldol reaction to the alpha position of the carbonyl of the substrate.

Pharmaceuticals

Oxazolidinones are mainly used as antimicrobials. The antibacterial effect of oxazolidinones is by working as protein synthesis inhibitors, targeting an early step involving the binding of N-formylmethionyl-tRNA to the ribosome.[1] (See Linezolid#Pharmacodynamics)

Some of the most important oxazolidinones are antibiotics.[2]

Examples of antibiotic oxazolidinones include:

  • Linezolid (Zyvox), which is available for intravenous administration and also has the advantage of having excellent oral bioavailability.
  • Posizolid, which appears to have excellent, targeted bactericidal activity against all common gram-positive bacteria, regardless of resistance to other classes of antibiotics.[3]
Chemical structure of tedizolid
  • Tedizolid, (Sivextro) which is approved for acute skin infections
  • Radezolid (RX-1741) has completed some phase-II clinical trials.[4]
  • Cycloserine is a second line drug against tuberculosis. Note that cycloserine, while technically an oxazolidone, has a different mechanism of action and substantially different properties from the aforementioned compounds.
  • Contezolid (S)-5-((isoxazol-3-ylamino)methyl)-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-2-one (MRX-I) has reported phase 1 data[5] and completed phase II trials in 2015, and is starting a phase 3 trial in 2016.[6]

An oxazolidinone derivative used for other purposes is rivaroxaban, which is approved by the FDA for venous thromboembolism prophylaxis.

History

Chemical structure of cycloserine

The first ever used oxazolidinone was cycloserine (4-amino-1,2-oxazolidin-3-one), a second line drug against tuberculosis since 1956.[7]

Developed during the nineties when several bacterial strains were becoming resistant against such antibiotics as vancomycin. Linezolid (Zyvox) is the first approved agent in the class (FDA approval April 2000).

Chemical structure of linezolid

The first commercially available 1,3-oxazolidinone antibiotic was linezolid, discovered and developed by Pharmacia & Upjohn.

Chemical structure of posizolid/AZD2563

In 2002 AstraZeneca began investigating posizolid, which is in clinical trials for use in humans.[8]

See also

References

  1. ^ Shinabarger, D. (1999). "Mechanism of action of the oxazolidinone antibacterial agents". Expert Opinion on Investigational Drugs. 8 (8): 1195–1202. doi:10.1517/13543784.8.8.1195. PMID 15992144.
  2. ^ Sonia Ilaria Maffioli (2014). "A Chemist's Survey of Different Antibiotic Classes". In Claudio O. Gualerzi; Letizia Brandi; Attilio Fabbretti; Cynthia L. Pon (eds.). Antibiotics: Targets, Mechanisms and Resistance. Wiley-VCH. ISBN 9783527659685.
  3. ^ Wookey, A.; Turner, P. J.; Greenhalgh, J. M.; Eastwood, M.; Clarke, J.; Sefton, C. (2004). "AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro". Clinical Microbiology and Infection. 10 (3): 247–254. doi:10.1111/j.1198-743X.2004.00770.x. PMID 15008947.
  4. ^ "Rx 1741". Rib-X Pharmaceuticals. 2009. Archived from the original on 2009-02-26. Retrieved 2009-05-17.
  5. ^ Gordeev, Mikhail F.; Yuan, Zhengyu Y. (2014). "New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile". Journal of Medicinal Chemistry. 57 (11): 4487–4497. doi:10.1021/jm401931e.
  6. ^ Inc, MicuRx Pharmaceuticals. "MicuRx Initiates Phase 3 Clinical Trial for MRX-I, A New Potent Oral Antibiotic Against Gram-positive Bacteria, Including MRSA". www.prnewswire.com. {{cite web}}: |last= has generic name (help)
  7. ^ A. W. Frahm, H. H. J. Hager, F. v. Bruchhausen, M. Albinus, H. Hager: Hagers Handbuch der pharmazeutischen Praxis: Folgeband 4: Stoffe A-K., Birkhäuser, 1999, ISBN 978-3-540-52688-9
  8. ^ Karpiuk, I; Tyski, S (2017). "Looking for the new preparations for antibacterial therapy. V. New antimicrobial agents from the oxazolidinones groups in clinical trials". Przeglad epidemiologiczny. 71 (2): 207–219. PMID 28872286.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=2-Oxazolidinone&oldid=1143738403"